Ireland, G., Mandal, S., Hickman, M., Ramsay, M., Harris, R., & Simmons, R. (2019). Mortality rates among individuals diagnosed with hepatitis c virus (HCV): An observational cohort study, England, 2008 to 2016. *Eurosurveillance, 24*(30), [1800695]. https://doi.org/10.2807/1560-7917.ES.2019.24.30.1800695
Mortality rates among individuals diagnosed with hepatitis C virus (HCV): an observational cohort study, England, 2008 to 2016

Georgina Ireland, Sema Mandal, Matthew Hickman, Mary Ramsay, Ross Harris, Ruth Simmons

1. National Infection Service, Public Health England, London, United Kingdom
2. The National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London, United Kingdom
3. The National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at University of Bristol, Bristol, United Kingdom
4. Population Health Sciences, Bristol Medical School, Bristol, United Kingdom

Correspondence: Georgina Ireland (Georgina.ireland@phe.gov.uk)

Citation style for this article:
Ireland Georgina, Mandal Sema, Hickman Matthew, Ramsay Mary, Harris Ross, Simmons Ruth. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. Euro Surveill. 2019;24(30):pii=1800695. https://doi.org/10.2807/1560-7917.ES.2019.24.30.1800695

Article submitted on 19 Dec 2018 / accepted on 12 Mar 2019 / published on 25 July 2019

Background: Monitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets. Aim: To estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008–16. Methods: An observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008–16) were calculated and compared to the general population. Results: Of 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30–69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population. Conclusions: Mortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.

Introduction
In England, an estimated 0.4% (160,000) of the population have chronic hepatitis C virus (HCV) infection, with the main group at risk of HCV infection being persons who inject drugs (PWID) [1]. Individuals with chronic HCV infection are at increased risk of liver cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC), the burden of which have been increasing over the past 10 years [2].

Historically, HCV treatment rates in England have been low, however, the treatment landscape for individuals with chronic HCV infection has dramatically changed following the introduction of direct-acting antivirals (DAAs) in 2014, which have a shorter treatment duration, are better tolerated and are more effective than previous interferon-based regimens [3]. Successful curative treatment, defined as a sustained virological response, improves the outcomes in individuals with HCV infection including reduced mortality rates [4-6]. With these changes to treatment it is important to understand the burden of disease and associated mortality in the pre-DAA era. This will enable us to effectively monitor their impact on the cascade of care (including mortality) taking into account the increased efforts to diagnose, engage in care and treat individuals with HCV infection. This is particularly relevant as countries across Europe, including the United Kingdom (UK), are working towards the World Health Organization (WHO) global strategy for elimination of viral hepatitis as a significant public health threat by 2030 and reduction in HCV-associated deaths is one of the metrics for monitoring progress [7].

Using information on testing from the Sentinel Surveillance of Blood Borne Virus Testing (SSBBV) and
Office for National Statistics (ONS) Death Registry in England, we aim to estimate mortality rates for individuals (≥15 years) first reported to SSBBV with diagnosed HCV infection between 2008 and 2016 and describe the characteristics of changes that have occurred following the introduction of DAAs in 2014.

Methods

Study design
This is an observational cohort study looking at HCV-related mortality rates in individuals aged 15 years or older, diagnosed with HCV infection between 2008 and 2016 in England.

Data sources

Sentinel Surveillance of Blood Borne Virus Testing (SSBBV)
The sentinel Surveillance of Blood Borne Virus Testing (SSBBV), held at Public Health England (PHE), collects hepatitis A-E, HIV and Human T-lymphotropic virus (HTLV) testing information from 23 participating laboratories in England. Information on tests is collected regardless of result and includes demographics (age, sex and ethnicity) and the service requesting the test [8,9]. Multiple tests relating to the same person are linked using a combination of soundex (phonetic algorithm for indexing names), date of birth, National Health Service (NHS) number and hospital number. Participating laboratories are broadly representative of England as a whole and cover ca 40% of the registered general practitioner (GP) population in England. When possible, the date of first HCV infection diagnosis in SSBBV is updated by the routine laboratory reports of HCV and Hospital Episode Statistics (HES). Diagnosis dates prior to those reported in SSBBV are identified in HES where an earlier inpatient stay is recorded with dates prior to those reported in SSBBV are identified. The routine laboratory reports of HCV and HES were linked to SSBBV using NHS number in conjunction with date of birth deterministically i.e. the data were first linked using NHS number in conjunction with date of birth (then dropping either the day, month or year), the data were then linked with soundex (a phonetic algorithm for indexing names) and initial before finally being linked with soundex and year of birth. In instances where the NHS number was not available, we matched on soundex, initial and date of birth. A hierarchical approach was used for each year where matches by NHS number superseded a match without an NHS number. Additional checks were conducted on records where a person had been tested after their date of death, where a person has been linked to a death recorded in a previous year and where multiple records matched.

SSBBV and the registry of deaths were linked using a deterministic approach i.e. the data were first linked using NHS number in conjunction with date of birth (then dropping either the day, month or year), the data were then linked with soundex (a phonetic algorithm for indexing names) and initial before finally being linked with soundex and year of birth. In instances where the NHS number was not available, we matched on soundex, initial and date of birth. A hierarchical approach was used for each year where matches by NHS number superseded a match without an NHS number. Additional checks were conducted on records where a person had been tested after their date of death, where a person has been linked to a death recorded in a previous year and where multiple records matched.

Office for National Statistics (ONS) cause of death registry
The registry of deaths at ONS, includes all reported deaths in England since 1937 [10]. Cause of death is coded according to the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10 [11]) as underlying cause or as one of nine contributory causes.

Data collection and linkage
In 2018, all individuals aged 15 years or older diagnosed with HCV infection and first reported to SSBBV between 2008 and 2016 were extracted from SSBBV. Individuals were excluded if they did not have date of birth or sex recorded. NHS laboratories in England submit positive HCV test results (predominantly anti-HCV, some HCV RNA) to the routine laboratory reporting of HCV at PHE. The system does not distinguish between anti-HCV and HCV RNA positivity and so laboratory ‘confirmed’ cases are a mix of current and ever infected individuals. Data have been collected since 1990, and since 2010, HCV infection has been a notifiable causative agent and all diagnostic laboratories are legally required to report new diagnoses to PHE. Data completion varies over time.

In April 2018, ONS provided all reported deaths between 2008 and 2016 in individuals aged 15 years or older living in England. Underlying cause of death ICD10 codes were grouped according to Table 1. In addition to the groupings we looked at: (i) all-liver disease mortality (underlying), by grouping liver cancer, ESLD, viral hepatitis, alcoholic and non-alcoholic liver disease diagnostic codes, and (ii) all-liver disease mortality (underlying and contributory), where liver cancer, ESLD, hepatitis, alcoholic and non-alcoholic liver disease were recorded as either the underlying or contributory (i.e. as any of the additional nine causes) cause of death.

Statistical analysis
Overall and disease-specific mortality rates per 100,000 person years (PY), standardised to the 2013 European standard population by age and sex, were calculated for all individuals (≥15 years) and within a subset of individuals aged 30–69 years (premature mortality). ASMRs for males and females are age-standardised only. Confidence intervals (CI) were calculated using the Poisson distribution [12]. Individual follow-up began 6 months after HCV diagnosis and ended at death (between 2008 and 2016) or 31 December 2016. Individuals who died within 6 months of their HCV diagnosis were excluded from the analysis, as there was potential bias towards higher rates of diagnosis in individuals with major morbidity. Annual age-sex adjusted mortality rates (ASMRs) were calculated for the period 2008 to 2016, allowing trends to be explored for all-cause, underlying and contributory all-liver disease mortality. The small number of people with HCV (who died) in 2008 and 2009 (due to very short follow-up...
times from diagnosis) led to unstable rates for the first 2 years of analysis and therefore ASMRs for these years were excluded when presenting trends. Joinpoint Regression Programme Version 4.2.1.0 (National Cancer Institute, Bethesda, United States) was used to analyse for changes in ASMRs at 2014, the year when DAAs were introduced in England. Joinpoint can identify statistically significant changes in trend data over time and whether there was a point at which a statistically significant change in the trend occurred [13].

For comparison, ASMRs for the general population were estimated using all death reports reported to ONS for 2012 divided by the mid-2012 population estimates, the mid-point of our analysis period. Mortality rate ratios were calculated by dividing the ASMR among individuals diagnosed with HCV infection between 2008 and 2016 by the ASMR among the English population in 2012 and 95% CI were calculated by dividing the ASMR 95% CI for individuals diagnosed with HCV by the ASMR for England.

Ethics
The data were collected for the surveillance of HCV infection, including linkage to death registrations held by the Office for National Statistics and is covered by Health Service (Control of Patient Information) Regulations 2002 (regulation 3).

Results
During the study period (2008–16), of 43,895 individuals (≥ 15 years) diagnosed with an HCV infection reported to SSBBV, 2,656 (6.3%) had died. Total follow-up time was 183,821 PY and median follow-up time was 4.1 years (interquartile range (IQR): 2.1–6.3 years). The majority of individuals with HCV infection were male (67.6%) and the median age at diagnosis was 39 years (IQR: 32–48 years) (Table 2). Of 2,656 individuals who died within the follow-up period, the median time from diagnosis to death was 3 years (IQR: 1.6–4.7 years).

All-cause ASMR per 100,000 among individuals with HCV infection were 2,834.2 per 100,000 PY (Table 3), 2.3 times higher than that for the general population (1,218.5 per 100,000 PY), and were higher in males than females (3,170.7 vs 2,497.7 per 100,000 PY). A non-significant decrease in ASMRs was observed from 2,523.4 per 100,000 PY (95% CI: 1,801.6–3,245.2) in 2010 to 2,438.2 per 100,000 PY (95% CI: 2,106.8–2,769.6) in 2016 (p = 0.30) (Figure). When examining the possibility of a change in trend in 2014, the year DAAs became available on the NHS, there was no significant difference between the two slopes of best fit (p = 0.34).

ASMRs for individuals with a HCV infection diagnosis were higher than those in the general population for all grouped underlying causes of death. Of note, mortality rate ratios indicate that compared with the general population, individuals with HCV infection were 421.9 times more likely to die from viral hepatitis, 34.5 times more likely from liver cancer, 8.0 times more likely from ESLD, 16.5 times more likely from alcoholic liver disease, 11.8 times more likely from non-alcoholic liver disease and 6.2 times more likely to die from external causes than the general population. When deaths from liver disease were grouped, ASMRs for underlying all-liver disease and underlying and contributory all-liver disease were 28.4 and 40.2 times higher, respectively, than for the general population. A non-significant decrease in ASMRs for underlying and contributory all-liver disease was observed, from 975.0 (95% CI: 619.1–1,331.0) in 2010 to 875.4 (95% CI: 395.9–1,054.9) in 2016 (p = 0.3).

Premature mortality
In individuals aged 30–69 years, all-cause ASMR was 1,768.9 per 100,000 PY among individuals with a HCV infection diagnosis, 4.7 times higher than the general population (England ASMR: 377.9 per 100,000 PY) (Table 3).

ASMRs per 100,000 PY in individuals aged 30–69 years were higher in men than women (2,016.5 vs 1,431.3 per 100,000 PY) and when compared with the general population. In this age group, ASMRs for all grouped causes of death were 263.6 times higher for viral hepatitis, 39.5 times higher for liver cancer, 16.8 times higher for alcoholic liver disease, 14.8 times higher for non-alcoholic liver disease, 8.9 times higher for ESLD and 11.2 times higher for external causes. ASMRs from underlying all-liver disease and underlying and

Table 1
Primary cause of death groupings, with ICD10 codes

| Cause of death grouping                  | IDC10 Codes                  |
|-----------------------------------------|------------------------------|
| Viral hepatitis                          | B15–19                       |
| End stage liver disease                  | I850, I983, K704, K720, K721, K729, K767, R18 |
| Liver cancer                             | C22                          |
| Alcoholic liver disease                  | K70, excluding K704           |
| Non-alcoholic liver disease              | K71-K77, excluding K720, K721, K729, K767 |
| External causes                          | S00–99, T00–98, V01–99, W00-W99, X00-X99, Y00-Y98 |
| Other                                    | All other ICD-10 codes        |
acquisition of infection [14]. Whilst there is limited literature on time from acquisition of HCV infection to HCV diagnosis, it is thought to be at least 10 years in PWID [15]. Our mortality rates, therefore, may not be representative of all individuals with HCV infection in England and maybe skewed towards those with more advanced HCV-related disease presenting with complications and these individuals may be more likely to be tested for HCV as a result. We do not have disease stage data to adjust for this potential bias, but linkage of routine laboratory reports of HCV infection to liver transplant registries showed a similar short duration to transplant registration. This bias may be reduced in our study through a variety of different means. First, it was not possible to include HCV RNA testing information with 25% of anti-HCV positive individuals having no HCV RNA test recorded in SSBBV; we would expect mortality rates in individuals with treated or cleared HCV infection to be lower than individuals currently infected. Second, SSBBV is derived from a network of laboratories that cover 40% of the England GP-registered population. It is possible that we may not have identified a person’s initial HCV test if they had tested outside the sentinel sites or before SSBBV. However, our cohort was also linked to routine laboratory reports of new diagnoses (established in 1996) and HES inpatient data (established in 2004) so any earlier diagnosis i.e. before SSBBV started, should have been identified. In addition, while coverage varies by region, the network is broadly representative for England and our analysis allowed inclusion of more people e.g. those testing positive but not necessarily referred or engaged in care, improving representativeness of our data. Third, there can be delays in death registrations, due to coroners’ inquests into cause of death being required. Around 5% of all deaths are not registered in the year they occurred, rising to 50% for deaths relating to drug poisonings. Our mortality rate estimates for external causes in more recent years might be an underestimate, therefore, but it is unlikely to impact liver disease [16].

Other evidence and implications
Our all-cause ASMRs were similar to those found in a study by Aspinall et al. based in Scotland [17]. There were some methodological differences (they calculated ASMRs for all individuals aged 1 years and over) and our mortality rates for liver cancer and alcohol associated liver disease were higher; this may be due to our larger sample size and only including individuals aged 15 years and over. We also found differences in ASMRs between males and females. This is likely to be associated with differences in co-morbidities e.g. smoking, alcohol and drug use [18,19], higher rates of spontaneous clearance of HCV and slower disease progression in females [20,21], which we were unable to adjust for. Alcohol misuse in HCV infected individuals can accelerate liver disease progression, which may explain the 15 times higher mortality rates from alcoholic liver disease [14,22].

**Discussion**

ASMRs for individuals diagnosed with HCV in England between 2008 and 2016 were more than two times higher than that found in the general population with higher rates in men than women. Mortality rates were between 8.0 and 421.9 times higher in individuals with HCV infection diagnosis for liver causes (ESLD, liver cancer, viral hepatitis, alcoholic and non-alcoholic liver disease) than for the general population and rates were 28.4 and 40.2 times higher, respectively, when underlying and contributory causes of death were included. Mortality rates for external causes were 6.2 times higher than in the general population and more pronounced in individuals aged 30–69 years. This may indicate a higher risk of premature mortality not only from liver related causes but also from overdose, intentional self-harm and accidents.

**Limitations**

A main limitation is that we were only able to analyse individuals diagnosed with HCV infection between 2008 and 2016, with the maximum follow-up time being 8.5 years, but HCV-associated disease, particularly ESLD, can take 20-30 years to develop following acquisition of infection [14].

---

**Table 2**

| Characteristics | Total | Deaths |
|-----------------|-------|--------|
|                 | n     | %      | n     | %      |
| **Sex**         |       |        |       |        |
| Male            | 29,671| 67.6   | 1,914 | 6.5    |
| Female          | 14,224| 32.4   | 742   | 5.2    |
| **Age**         |       |        |       |        |
| 15–29           | 8,007 | 18.2   | 143   | 1.8    |
| 30–39           | 14,415| 32.8   | 494   | 3.4    |
| 40–49           | 12,225| 27.9   | 733   | 6.0    |
| 50–69           | 8,228 | 18.7   | 948   | 11.5   |
| 70+             | 1,020 | 2.3    | 338   | 33.1   |
| **Ethnicity**   |       |        |       |        |
| White           | 28,599| 65.2   | 2,311 | 8.1    |
| Asian           | 3,984 | 9.1    | 200   | 5.0    |
| Black           | 828   | 1.9    | 77    | 9.3    |
| Other           | 1,249 | 2.8    | 44    | 3.5    |
| Unknown         | 9,235 | 21.0   | 24    | 0.3    |
| **Diagnosis year** |       |        |       |        |
| 2008–10         | 16,122| 36.7   | 1,554 | 9.6    |
| 2011–13         | 15,545| 35.4   | 874   | 5.6    |
| 2014–16         | 12,228| 27.9   | 228   | 1.9    |

HCV: hepatitis C virus; SSBBV: Sentinel Surveillance of Blood Borne Virus Testing.
### Table 3

All-cause, sex-specific and disease-specific ASMR, per 100,000 person years, for individuals diagnosed with HCV infection, England, 2008–2016

| Characteristics                  | England Diagnosed with HCV infection | Mortality rate ratio |
|----------------------------------|--------------------------------------|----------------------|
|                                  | ASMR  | 95% CI | PY | Deaths | Crude mortality rate | ASMR  | 95% CI | Mortality ratio | 95% CI |
| **Age ≥15 years**                |       |        |    |        |                    |       |        |                |       |
| Total                            | 1,218.5 | 1,214.9–1,222.1 | 183,821 | 2,656 | 1,444.9 | 2,834.2 | 2,664.2–3,004.2 | 2.3 | 2.2–2.5 |
| **Sex**                          |       |        |    |        |                    |       |        |                |       |
| Male                             | 1,391.1 | 1,385.2–1,397.0 | 123,022 | 1,914 | 1,555.8 | 3,170.7 | 2,927.2–3,414.1 | 2.3 | 2.1–2.5 |
| Female                           | 1,045.9 | 1,041.7–1,050.1 | 60,799  | 742   | 1,220.4 | 2,497.7 | 2,260.4–2,735.0 | 2.4 | 2.2–2.6 |
| **Cause of death**               |       |        |    |        |                    |       |        |                |       |
| Liver Cancer                     | 10    | 9.6–10.3 | 183,821 | 233  | 126.8 | 344.4 | 283.8–405.1 | 34.5 | 28.5–40.6 |
| ESLD                             | 3.4   | 3.3–3.6 | 183,821 | 63   | 34.3 | 27.5 | 18.3–36.8 | 8.0 | 5.3–10.7 |
| Viral hepatitis                  | 0.5   | 0.5–0.6 | 183,821 | 207  | 112.6 | 220.5 | 175.8–265.3 | 421.9 | 336.3–507.6 |
| Non-alcoholic liver disease      | 6.5   | 6.2–6.7 | 183,821 | 100  | 54.4 | 76.6 | 54.0–99.2 | 11.8 | 8.3–15.3 |
| Alcoholic liver disease          | 7.4   | 7.1–7.7 | 183,821 | 238  | 129.5 | 222.0 | 100.4–143.6 | 16.5 | 13.6–19.4 |
| All-liver disease (underlying)   | 27.8  | 27.3–28.3 | 183,821 | 841  | 457.5 | 791.1 | 709.0–873.2 | 28.4 | 25.5–31.4 |
| All-liver disease (underlying and contributory) | 28.5 | 27.9–29.0 | 183,821 | 1213 | 659.9 | 1145.1 | 1,049.9–1,245.2 | 40.2 | 36.7–43.7 |
| External causes                  | 35.8  | 35.2–36.4 | 183,821 | 536  | 291.6 | 221.2 | 193.4–248.9 | 6.2 | 5.4–6.9 |
| Other                            | 1,154.8 | 1,151.3–1,158.4 | 183,821 | 1279 | 695.8 | 1821.9 | 1,675.7–1,968.1 | 1.6 | 1.5–1.7 |
| **Age 30–69 years**              |       |        |    |        |                    |       |        |                |       |
| Total                            | 377.9 | 375.5–380.2 | 161,622 | 2165 | 1,339.5 | 1,768.9 | 1,672.3–1,865.5 | 4.7 | 4.4–4.9 |
| **Sex**                          |       |        |    |        |                    |       |        |                |       |
| Male                             | 456.8 | 451.1–458.5 | 111,618 | 1,639 | 1,468.4 | 2,016.5 | 1,978.4–2,234.7 | 4.4 | 4.3–4.9 |
| Female                           | 300.9 | 298.0–303.9 | 50,005  | 517   | 1,033.9 | 1,431.3 | 1,286.7–1,575.8 | 4.8 | 4.3–5.2 |
| **Cause of death**               |       |        |    |        |                    |       |        |                |       |
| Liver Cancer                     | 5.2   | 5.0–5.5 | 161,622 | 175  | 108.3 | 206.8 | 169.8–243.7 | 39.5 | 32.4–46.5 |
| ESLD                             | 4.2   | 4.0–4.5 | 161,622 | 60   | 37.1  | 37.7 | 24.6–49.1 | 8.9 | 6.2–11.6 |
| Viral hepatitis                  | 0.6   | 0.5–0.7 | 161,622 | 173  | 107.0 | 165.2 | 134.0–196.4 | 263.6 | 213.8–313.4 |
| Non-alcoholic liver disease      | 5.1   | 4.9–5.4 | 161,622 | 91   | 56.3  | 76.4 | 56.5–96.3 | 14.8 | 11.0–18.7 |
| Alcoholic liver disease          | 10.1  | 9.7–10.5 | 161,622 | 232  | 143.5 | 169.4 | 142.8–196.0 | 16.8 | 14.1–19.4 |
| All liver-disease (underlying)   | 25.4  | 24.8–26.0 | 161,622 | 731  | 452.3 | 655.5 | 595.8–715.3 | 25.8 | 23.5–28.2 |
| All liver-disease (underlying and contributory) | 36.4 | 35.7–37.1 | 161,622 | 1,049 | 649.0 | 917.8 | 847.1–988.4 | 25.2 | 23.3–27.1 |
| External causes                  | 24.5  | 23.9–25.1 | 161,622 | 499  | 308.7 | 274.2 | 244.8–303.6 | 11.2 | 10.0–12.4 |
| Other                            | 328.1 | 325.9–330.2 | 161,622 | 926  | 572.9 | 839.1 | 769.2–909.1 | 2.6 | 2.3–2.8 |

ASMR: age and sex-standardised mortality rates; CI: confidence interval; ESLD: end stage liver disease; HCV: hepatitis C virus; PY: person years.

a Individuals with liver cancer, ESLD, viral hepatitis, alcoholic liver disease and non-alcoholic liver disease recorded as an underlying cause, or any of the additional nine causes recorded.
Analysis with Joinpoint did not show a statistically significant decrease in all-cause and underlying and contributory all-liver disease mortality following the introduction of HCV treatment with DAAs in 2014; however the data does suggest that mortality rates have started to fall. Unlinked analysis of mortality records in England found a 3% reduction in the number of deaths from HCV-related ESLD and liver cancer in 2016 and a further 11% fall in 2017 [23], which have been largely attributed to improved access to new treatments. However, under-reporting of HCV infection remains an issue in mortality records [24-26]. The impact of DAAs and cascade of care improvements on mortality rates, will likely be more pronounced over time, as treatment restrictions are relaxed to include patients with little or no liver disease – thus preventing progression to severe liver disease with lower SVRs and higher mortality risk. A small rise in mortality rates in 2014 was notable, which although not significant, might have occurred due to patients deferring treatment with interferon-based regimes until they became eligible for treatment with DAAs.

When compared with England’s general population we found all-cause mortality rates were 2.3 times higher for all adults and 4.6 times higher for individuals 30–69 years old with a HCV infection diagnosis. These high rates of premature mortality are worrying and highlight health inequalities as this younger group are likely to include a sub-group of vulnerable PWID, who tend to have multi-substance addictions, mental health issues and chaotic lifestyles. Their mortality risk, therefore, is not only from liver causes, but also from accidents, international self-harm and drug-related poisonings. This was evident in our findings, with an almost doubling of risk of death from external causes in the 30–69 age group compared with all adults with HCV. Simmons et al. [24] also found external causes to be the most common cause of death for individuals anti-HCV positive over the same period and drug-related mortality in England has been increasing over the last decade [16]. While DAAs have an important role to play, solutions to address problematic drug use (the most common mode of transmission for HCV in England) are also important to prevent onward HCV spread and to reduce premature mortality from liver and drug-associated deaths.

While clinical studies are required to prove the impact of DAAs on HCV-associated outcomes, they are not

**Figure**

ASMR by all-cause mortality and underlying and contributory all-liver mortality for individuals aged 15 years and over, England, 2010–2016

![ASMR](image-url)
sufficient to monitor progress towards the WHO elimination goals. Numerous European countries reported having surveillance of HCV and mortality in a recent WHO survey [27] and as HCV infection is often under-detected, mortality records, linked analysis is required to understand the true burden of HCV-associated disease [24-26]. As Europe works towards the elimination of HCV and progress monitoring is required, this methodology offers a cost-effective option for analysis in countries with suitable datasets.

Conclusion
Mortality rates, particularly in younger individuals, were higher in those with a diagnosis of HCV infection compared with the general English population, highlighting health inequalities. Our findings provide a baseline of HCV-associated mortality rates pre-DAA and continued monitoring is required as HCV treatments are scaled up to attain HCV elimination ambitions. However, the high mortality rates associated with common co-morbidities, such as problematic drug and alcohol use, highlights the importance of integrated health and social care strategies and commissioning to address the needs of this vulnerable population and reduce inequalities. A holistic approach to drug misuse is required to reduce the double jeopardy of drug and HCV-associated mortality experienced by individuals with HCV infection.

Acknowledgements

We thank the NIHR HPRU in Blood Borne and Sexually Transmitted Infections Steering Committee: Caroline Sabin (Director), Anthony Nardone (PHE Lead), Catherine Mercer, Gwenda Hughes, Jackie Cassell, Greta Rait, Samreen Ijaz, Tim Rhodes, Khouloud Porter, Sema Mandal and William Rosenberg, and the NIHR HPRU in Evaluation of Interventions at the University of Bristol in partnership with Public Health England.

We are grateful to the late Sam Lattimore for his contribution to sentinel surveillance of blood-borne viruses and his vision and formative work on data linkage between hepatitis datasets.

Funding: This report is independent research by the National Institute for Health Research. The research was funded by the National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at UCL in partnership with Public Health England (PHE) and in collaboration with the London School of Hygiene and Tropical Medicine. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health or Public Health England.

Conflict of interest
Public Health England (GI, RS, MR and SM) was commissioned by Gilead Sciences to write a report on HCV testing in England and MH have received speaker fees from Gilead, Abbvie and MSD.

Authors’ contributions
RS matched the two datasets and GI undertook the analysis and drafted the manuscript. SM, MH, MR, RH and RS provided critical input to the manuscript and approved all revisions.

References
1. Public Health England (PHE). Hepatitis C in England, 2018 report- Working to eliminate hepatitis C as a major public health threat. 2018. London: PHE; 2018. [accessed Dec 2018]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/798270/HCV_in-England_2019.pdf
2. Public Health England (PHE). Hepatitis C in the UK- 2015 report. 2015; London: PHE; 2015. [accessed Dec 2018]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/448710/New_FINAL_HCV_2015_IN_THE_UK_REPORT_28072015_v2.pdf
3. Thompson AJ, Holmes JA. Treating hepatitis C - what’s new? Aust Prescr. 2013;36(6):191-7. https://doi.org/10.18773/austprescr.2015.068 PMID: 2684371
4. Singal AG, Volk ML, Jensen D, Bi Bisceteg AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):288-9, 288.e1. PMID: 19948249
5. Simmons B, Saleem j, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730-40. https://doi.org/10.1093/cid/civ396 PMID: 25987643
6. Farrel F, Fontaine H, Dorival C, Simony M, Diazia A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453-64. https://doi.org/10.1016/S0140-6736(18)32111-1 PMID: 3076523
7. World Health Organization (WHO). Global Health Sector Strategy on Viral Hepatitis 2016-2021- Towards ending viral hepatitis. 2016. Geneva; WHO; 2016. [accessed Dec 2018]. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=B44D16065983178E35218852A8F79E6A?sequence=1
8. Public Health England (PHE). Annual report from the sentinel surveillance study of blood borne virus testing in England: data for January to December 2017, 2018; London: PHE; 2018. [accessed Dec 2018]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/746267/hrp3618_bbv-ss.pdf
9. Brant LJ, Hurrell M, Balogun MA, Klapper P, Ahmad F, Boxall E, et al. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiol Infect. 2007;135(3):417-26. https://doi.org/10.1017/S0014023807005656
10. Office for National Statistics (ONS). Reference for birthsdeathsandmarriages/deaths/methodologies/ joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-51. https://doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z PMID: 10649300
11. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for jointpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-51. https://doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z PMID: 10649300
12. National Health Service Scotland (NHS Scotland). Standardisation Guidance: Calculation of standardised rates and ratios: Direct and indirect methods. 2016. Edinburgh: NHS Scotland; 2016. [accessed Dec 2018]. Available from: https://www.scotchco.org.uk/media/1540/p/phil-standardisation-guidance-v2.1.docx
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DORSVIRC groups. Lancet. 1997;349(9055):825-32. https://doi.org/10.1016/S0140-6736(96)67042-8 PMID: 9121257
14. Sutton AJ, Gay NJ, Edmunds WJ, Hope VO, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C
in injecting drug users in England and Wales. BMC Infect Dis. 2006;6(1):93. https://doi.org/10.1186/1471-2334-6-93 PMID: 16762050

16. Office for National Statistics (ONS). Deaths related to drug poisoning in England and Wales: 2017 registrations 2018. Newport: ONS; [accessed Aug 2010]. Available from: https://www.gov.uk/government/statistics/deaths-related-to-drug-poisoning-in-england-and-wales-2017-registrations

17. Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol. 2015;62(2):269-77. https://doi.org/10.1016/j.jhep.2014.09.001 PMID: 25200903

18. Public Health England (PHE). Unlinked anonymous HIV and viral hepatitis monitoring among PWID: 2018 report. 2018. London: PHE; 2018. [accessed Dec 2018]. Available from: https://www.gov.uk/government/publications/substance-misuse-treatment-for-adults-statistics-2017-2018

19. Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol. 2015;62(2):269-77. https://doi.org/10.1016/j.jhep.2014.09.001 PMID: 25200903

20. Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: does sex play a role? J Infect Dis. 2014;209(Suppl 3):S81-5. https://doi.org/10.1093/infdis/jiu057 PMID: 24966194

21. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut. 2006;55(8):1183-7. https://doi.org/10.1136/gut.2005.078147 PMID: 16434426

22. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27(6):1730-5. https://doi.org/10.1002/hep.510270637 PMID: 9620330

23. Public Health England (PHE). Hepatitis C in the UK, 2018 report: Working to eliminate hepatitis C as a major public health threat. 2018. London: PHE; 2018. [accessed Dec 2018]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/732469/HCV_IN_THE_UK_2018_UK.pdf

24. Simmons R, Ireland G, Ijaz S, Ramsay M, Mandal S. Unpublished: Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study. Journal of Viral Hepatitis. 2019. Vol 26, Issue 7: 873-880.

25. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (ChHeCS), 2006-2010. Clin Infect Dis. 2014;58(8):1055-61. https://doi.org/10.1093/cid/ciu077 PMID: 24523214

26. Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour J-F, Moradpour D, et al. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat. 2018;25(2):152-60. https://doi.org/10.1111/jvh.12803 PMID: 29159841

27. Lazarus Jv, Mozalevskis A, Safreed-Harmon K, Eramova I. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014). Hepatol Med Policy. 2016;1(1):3. https://doi.org/10.1186/s41124-016-0009-5 PMID: 30288307

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2019.